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Abstract
Lactobacillus strains with probiotic activity are major constituents of numerous common food products. Due to their ‘generally regarded
as safe’-status (GRAS-status), Lactobacillus strains can also be genetically engineered for use in oral immunotherapeutic applications,
such as vaccination and T lymphocyte tolerance induction in autoimmune disease.
In the current study, we demonstrate that the growth phase of orally administered individual Lactobacillus strains can differentially affect
antigen-specific antibody subclasses IgG1 and IgG2a, which might reflect skewing of systemic activity of T helper cell type 2 (Th2) and
T helper cell type 1 (Th1) pathways, respectively. Mice were orally fed different wild type Lactobacillus strains in log phase or stationary
phase and immunized intraperitoneally with a T-cell dependent protein antigen. Sera were evaluated for the ratio of antigen-specific IgG1
and IgG2a antibodies. Stationary Lactobacillus murines and Lactobacillus casei cultures, but not two other Lactobacillus strains, evoked
significantly higher IgG1/IgG2a ratios than log phase cultures, possibly relating to increased activity of the Th2-pathway. Despite normal
variation in antibody responses against TNP–CGG among individual mice, a high correlation was found between the IgG1 and IgG2a
responses of mice within experimental groups. This differential antibody response is likely due to growth phase-dependent differences in
bacterial cell composition.
Since Lactobacillus growth phase dependent skewing of antibody responses possibly reflecting T-cell pathways can inadvertently affect
allergic and (auto)-immune responses, the current findings strongly caution against unidimensional views on the oral administration
of individual Lactobacillus strains for probiotic or immunotherapeutic purposes, but also suggest additional possibilities for immune
modulation.
© 2003 Elsevier Science Ltd. All rights reserved.
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1. Introduction
The genus Lactobacillus belongs to the family of Lac-
tobacteriaceae, also known as lactic acid bacteria, a group
of microorganisms that have been used for centuries in
bio-processing and preservation of food and feed. Some
Abbreviations: GRAS, generally regarded as safe; DTH, delayed type
hypersensitivity; TNP, trinitrophenyl; CGG, chicken gamma globulin;
PVC, polyvinyl chloride; a.u., arbitrary unit; EAE, experimental autoim-
mune encephalomyelitis; DC, dendritic cell
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fermented dairy products containing Lactobacillus species
are believed to have certain health promoting properties for
humans, including enhancement of immune responses (ad-
juvanticity) and anti-carcinogenic activity. As lactobacilli
are commensals of the gut and are generally regarded as
safe (GRAS-status), lactobacilli are good candidates for use
as production and delivery hosts of heterologous proteins in
food but also health care products. Genetically engineered
lactobacilli expressing bacterial or viral proteins on the
cell surface can potentially be used as oral vaccines [1,2].
On the other hand, Lactobacillus recombinants secreting
tolerogenic autoantigens can be used to induce systemic
peripheral T-cell tolerance by oral administration for treat-
ment of autoimmune disease [1].
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Clearly, there is accumulating evidence that lactobacilli
possess properties that are beneficial in a diverse range
of diseases, including infections, allergy and cancer [3–8].
However, due to the diversity of species within the Lacto-
bacillus genus not each Lactobacillus strain possesses sim-
ilar health stimulating properties. For instance, it has been
shown that Lactobacillus strains differ in their ability to en-
hance the humoral immune response (adjuvant activity) and
that they induce distinct cytokine profiles in the gut after oral
administration [9,10]. This implies that strain selection is a
crucial issue for the use of wild type Lactobacillus strains
in food products, but also when recombinant lactobacilli are
to be used to promote different types of immune responses
such as vaccination, T-cell tolerance induction and treatment
of allergy.
Most immune responses are centrally regulated by the ac-
tivity of two functionally polarized T helper cell types, Th1
versus Th2 cells (reviewed in [11]). Th1 cells producing
IFN- and IL-12 promote cellular immune responses in-
cluding macrophage activation, delayed type hypersensitiv-
ity (DTH) and cytotoxicity. Th1 cells positively contribute
to the humoral (antibody) response to a limited extent by
supporting the production of the IgG2a antibody subclass,
but they inhibit production of several other subclasses like
IgG1. Although the Th1 pathway is crucial for protection
against many pathogens, it may also be the predominating
type of response in chronic inflammatory autoimmune dis-
eases like multiple sclerosis and insulin-dependent diabetes
mellitus [11–13].
Th2 cells produce IL-4, IL-5 and IL-10, which are gener-
ally regarded to be anti-inflammatory. These cytokines are
involved in stimulating strong antibody production by B cells
(e.g. IgG1, IgM and IgE), stimulation of eosinophils and
mast cells, as well as deactivation of macrophages. Domi-
nant Th2 responses may contribute to diseases such as atopic
allergy. In mice, production of IgG1 versus IgG2a is widely
interpreted as a reflection of differential Th2–Th1 reactiv-
ity. Since differential functional capabilities of IgG1 versus
IgG2a have been documented extensively, for instance with
respect to complement fixation, the IgG1/IgG2a ratio can
be regarded as an indirect reflection of immune function in
vivo.
A multitude of approaches to skew T helper cell path-
ways to treat human diseases is under intense investigation
[14]. When oral bio-therapy with wild type Lactobacillus
strains or genetically engineered recombinants [1,15,16]
is considered, the way these strains impinge on T helper
pathways is an important factor determining success-
ful application. Therefore, the aim of the present study
was to establish whether orally administered individual
Lactobacillus strains can differentially affect IgG1 (Th2)
versus IgG2a (Th1) antibody responses against system-
ically administered exogenous protein antigen, possi-
bly reflecting T helper cell pathways and whether such
skewing is dependent on the growth phase of the lacto-
bacilli.
2. Materials and methods
2.1. Animals and Lactobacillus strains
Female SJL/J mice (Erasmus University Rotterdam, The
Netherlands) were kept under filtertop hoods in a DII facility
with free access to mouse chow and acidified water (pH 2.8).
Experiments were performed according to regulations in the
Dutch law on animal experimentation.
The Lactobacillus strains L. reuteri ML1 and L. murines
CNRZ were originally isolated from mouse. The strains L.
casei ATCC 393 and L. plantarum NCIB 8826 were origi-
nally isolated, respectively, from cheese and human saliva.
2.2. Culturing of Lactobacillus strains
All Lactobacillus strains were cultured overnight, in 5 ml
MRS broth followed by 15 ml MRS broth (Difco, Detroit,
MI), before inoculation in 500 ml MRS broth (1:50). The
cultures were grown to late log phase (6 h) or stationary
phase (16 h). The cells were harvested, washed twice with
PBS and once with 0.2 M NaHCO3. This extensive washing
was performed to ensure no secreted Lactobacillus prod-
ucts were present in the suspension. Before use the cells
were resuspended in 0.2 M NaHCO3. From this suspension
a sample was taken for plating on MRS broth plates for the
calculation of the number of colony forming units (CFU) as
well as to rule out contamination.
2.3. Oral administration of Lactobacillus strains and
immunization schedule
To investigate the effect of orally administered lacto-
bacilli on the humoral immune response, mice orally re-
ceived wild type lactobacilli, prepared as described earlier,
on four consecutive days. Each animal received approxi-
mately 1010 CFU per intra-gastric administration. On the
first day, the mice were also immunized intraperitoneally
with 25g of the hapten trinitrophenyl (TNP) conjugated
to the thymus dependent antigen chicken gamma globulin
(CGG; Sigma, La Jolla, CA). One control group was im-
munized with TNP–CGG in a water-in-oil adjuvant, specol
[17], which resembles Freund’s incomplete adjuvant. From
day 49 onwards, oral administration of lactobacilli as well
as intra-peritoneal immunization with TNP–CGG was re-
peated as above. This day was chosen as titers had declined
to below 50% of maximal values. Blood samples were taken
before the start of the experiment and every 7 days.
2.4. Semi-quantitative ELISA
Serum titers of CGG and TNP specific antibodies after
immunization with TNP–CGG were determined by ELISA.
Polyvinyl chloride (PVC) microtiter plates (Titertek, Flow
Laboratories, Irvine, Scotland) were coated with CGG
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(5g/ml, 50l/well) or TNP–BSA (5g/ml, 50l/well)
overnight at 4 ◦C. Non-specific antibody binding was
blocked by incubation with 0.2% gelatin in PBS (50l/well)
for 1 h at 25 ◦C. Subsequently the plates were incubated for
1 h at 25 ◦C with dilutions of TNP–CGG induced antisera
and pre-immune sera to correct for background reactivity.
For the detection of IgG antibodies specific for CGG or TNP,
alkaline phosphatase-labelled goat anti-mouse IgG (KPL,
Gaithersburg, MD) was used. For the detection of CGG or
TNP specific IgG1 or IgG2a antibodies, rabbit anti-mouse
IgG1 or rabbit anti-mouse IgG2a antibodies (ICN Immuno-
biologicals, Costa Mesa, CA) were used, respectively, fol-
lowed by 1 h incubation with alkaline phosphatase-labelled
swine anti-rabbit Ig antibodies (Dako A/S, Glostrup, Den-
mark). After addition of the substrate para-nitrophenyl
phosphate, the absorbance was read at 405 nm. An IgG1
monoclonal antibody directed against CGG was used as
reference for detection of IgG and IgG1 CGG specific an-
tibodies on each ELISA-plate. A polyclonal mouse serum
containing high levels of IgG2a antibodies specific for
CGG was used as reference in the ELISAs to detect IgG2a
specific antibodies against CGG. The reference used in all
TNP-specific ELISAs was a polyclonal mouse serum with
high levels of IgG1 and IgG2a TNP-specific antibodies.
Relative concentrations of IgG1, IgG2a and total IgG were
calculated after subtraction of the absorbance of pre-immune
sera at the corresponding dilutions. The linear part of the
reference curve was used to perform linear regression. Only
those measurements of the test sera falling within the same
absorbance range as reference samples used for regression
(with comparable slope), were used for the calculation of the
relative concentrations of IgG1, IgG2a and IgG in arbitrary
units (a.u.).
To detect antibody responses against Lactobacillus
murines after oral administration, PVC plates were coated
with fragmented L. murines (50 ng/ml, 50l/well). The
fragments were obtained by sonification of cells harvested
after overnight growth in MRS broth. The following incu-
bation steps and development were performed as described
for total IgG. Serum obtained after intra-peritoneal immu-
nization of mice with L. casei in adjuvant (Difco’s complete
adjuvant, Difco) was used as reference.
2.5. Statistical analysis
A single factor ANOVA was used to analyze the data. As
the groups of mice were too large to be held in one cage,
it was calculated whether there were differences between
cages holding mice of the same group. Since this was not
the case, the t-alfa for students t-test could be used to calcu-
late the least significant differences instead of the F-alfa of
the F-test. When P < 0.05 the difference was interpreted
as significant. This approach was used to compare the total
IgG antibody responses and the IgG1/IgG2a responses of
the groups on 1 day (Figs. 1 and 2). When the IgG1/IgG2a
ratios were compared over time (7, 14 and 21 days after
Fig. 1. Four wild type Lactobacillus strains do not enhance systemic
antibody responses. Total IgG antibody responses against CGG were
determined in sera of mice immunized i.p. with TNP–CGG in PBS
(n = 5). One control group was immunized with TNP–CGG in adjuvant.
The mice received wild type lactobacilli in NaHCO3 orally on four
consecutive days. The lactobacilli were grown to log phase (white bars)
or stationary phase (black bars). The control groups received NaHCO3
buffer only (hatched bars). The immunization with TNP–CGG as well
as the oral administration procedure was repeated from day 49 onwards.
Results (±S.E.M.) obtained with sera collected 14 days after this second
immunization are shown. A reference curve was used to calculate the
arbitrary units; stat, stationary.
the second immunization), linear regression was performed
on the data of each individual animal. The same procedure
as used for the single data points was applied to the re-
gression lines (Fig. 4). Differences between the intercepts
indicate different IgG1/IgG2a ratios. Distinct slopes indi-
cate difference in change of the ratios over time. Linear re-
gression was performed to calculate the correlation lines in
Fig. 3.
3. Results and discussion
3.1. Four wild type Lactobacillus strains do not enhance
systemic antibody responses
In order to investigate whether different Lactobacillus
strains have different intrinsic adjuvanticity (defined as
the capability to non-specifically enhance the antibody re-
sponse), four wild type Lactobacillus strains were orally
administered to SJL/J mice (n = 5). SJL/J mice are biased
towards the Th1 pathway and are susceptible to induction
of experimental autoimmune diseases such as experimental
autoimmune encephalomyelitis (EAE), a model for multi-
ple sclerosis. The bacteria were grown to log phase (6 h) or
stationary phase (16 h) to investigate whether the intrinsic
adjuvanticity is growth phase dependent. The mice received
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Fig. 2. Two wild type Lactobacillus strains skew the IgG1/IgG2a ratio
dependent on growth phase. Mice (n = 5) were immunized i.p. with
TNP–CGG in PBS and fed with wild type Lactobacillus strains in log
(white bars) or stationary phase (black bars). The control groups orally
received NaHCO3 only (hatched bars) and were immunized i.p. with
TNP–CGG in PBS or adjuvant. The IgG1 and IgG2a responses were
calculated in arbitrary units with the use of reference curves. The ratio
between IgG1 and IgG2a antibodies specific for CGG was calculated for
sera obtained 14 days after the second immunization with TNP–CGG
(±S.E.M.). Significance of differences observed between groups of mice
fed log or stationary phase cultures of the same Lactobacillus strain is
indicated; stat, stationary.
one of the wild type Lactobacillus strains, L. plantarum
NCIB, L. reuteri, L. murines or L. casei in NaHCO3 orally
on four consecutive days. The control groups received
NaHCO3 only. On the first day, the mice were also immu-
nized i.p. with TNP–CGG in PBS. One control group was
immunized with TNP–CGG in adjuvant. Total IgG antibody
responses against CGG were determined in sera collected
14 days after the second immunization (Fig. 1). None of the
tested Lactobacillus strains exhibited intrinsic adjuvanticity
in SJL mice, as no significant differences between groups
fed Lactobacillus strains and the control group immunized
with TNP–CGG in PBS and fed with NaHCO3 only were
seen. These data are consistent with results obtained with
log phase Lactobacillus strains in the Th2-biased BALB/c
mouse strain, except for L. reuteri [9]. This strain did en-
hance the antibody response against CGG in BALB/c mice.
In addition, no significant differences between log and sta-
tionary phases lactobacilli fed groups were present in SJL/J
mice, indicating that in this Th1-biased mouse strain, the
growth phase of these Lactobacillus species does not affect
adjuvant activity. As expected, the control group immunized
with TNP–CGG in adjuvant showed a significant and strong
increase in CGG-specific antibody levels when compared
to all other groups (P < 0.01). Total IgG responses against
TNP were lower but comparable to the anti-CGG responses.
Fig. 3. L. murines of different growth phases induce distinct but constant
IgG1/IgG2a ratio’s. Mice (n = 8) were fed L. murines in stationary or
log phase. Sera obtained 21 days after the second immunization with
TNP–CGG were tested for IgG1 and IgG2a antibody responses against
CGG. IgG1 and IgG2a responses are indicated in arbitrary units which
were calculated with the use of reference curves. The IgG2a response of
two animals in the group fed log phase L. murines was too low to be
calculated. These mice were excluded from the analysis to prevent undue
further emphasis on the existing clear difference between the groups. Each
circle represents an individual animal. Mice fed log phase L. murines are
indicated by () and mice fed stationary phase L. murines are indicated
by (). The correlation lines were calculated by linear regression. The
variance is 0.67 for the group fed log phase L. murines and 0.85 for the
group fed stationary phase cultures. R = 0.43 for the group fed log phase
cultures and R = 2.43 for the group fed stationary phase cultures.
3.2. Two wild type Lactobacillus strains skew the
IgG1/IgG2a ratio dependent on growth phase
Although no significant differences occurred in the total
IgG response of mice fed log or stationary phase cultures
of the same Lactobacillus strain, the antibody response
might be qualitatively different. For mice, it is generally
accepted that the IgG1 response reflects helper activity of
Th2 CD4+ T-cells, where IgG2a results from Th1-activity.
Therefore, the IgG1 and IgG2a responses against CGG
were calculated for sera obtained 14 days after the sec-
ond immunization and were expressed as the IgG1/IgG2a
ratio (Fig. 2). Oral administration of a stationary phase
culture of L. casei or L. murines lead to a significantly
higher IgG1/IgG2a ratio than log phase bacteria of the
same strain (P < 0.01). Although L. plantarum NCIB
induced a similar pattern of IgG1/IgG2a ratios, the differ-
ence did not reach significance. L. reuteri did not show
a difference in IgG1/IgG2a ratio between log and sta-
tionary phases cultures. Because of the differences found
between Lactobacillus strains, it can be concluded that
this isotype skewing is growth phase-dependent as well as
bacterial strain-dependent. Although the anti-TNP IgG2a
responses in many cases were too low to properly calculate
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IgG1/IgG2a ratios, the ratios that were calculated showed a
similar trend as the ratios for anti-CGG (data not shown).
3.3. No systemic antibody response against L. murines
after oral administration
From the previous experiments it was clear that some
Lactobacillus strains are able to skew the IgG1/IgG2a re-
sponse dependent on their growth phase. In addition to L.
casei, L. murines showed a growth phase-dependent differ-
ence in IgG1/IgG2a ratio. L. murines was selected for fur-
ther investigation. One of the rationales to use lactobacilli
for oral vaccination or other therapeutical purposes is the
fact that they are commensals of the human gut [18,19] and
are generally regarded as safe (GRAS-status). In addition,
they should be non-immunogenic reflected in an inability to
evoke antibody responses against themselves. To evaluate
this in the current experimental setting, a similar experimen-
tal design as in Figs. 1 and 2 was used. Total IgG and IgM
responses of SJL/J mice (n = 8) against L. murines were
determined by ELISA in pooled sera obtained 21 days after
the second intra-peritoneal immunization with TNP–CGG
and oral administration of L. murines. As expected, the
treatment protocol did not induce IgG responses against L.
murines itself. For L. murines an absorbance of 0.26 was
measured for log phase cultures and 0.22 for stationary cul-
tures, versus absorbances of 0.25 for normal mouse serum
and 0.34 for mice which received NaHCO3 only. No IgM re-
sponse could be detected either (data not shown). In contrast,
when separate mice were immunized intraperitoneally with
L. murines in adjuvant as a positive control group, high IgG
responses against L. murines itself occurred (OD (405 nm)
= 1.07). These data confirm that oral administration of L.
murines does not induce antibody responses against the bac-
teria, and imply that growth phase-dependent skewing of the
TNP–CGG specific IgG1/IgG2a ratio is not related to an
antibody response against the bacteria.
3.4. L. murines of different growth phases induce distinct
but constant IgG1/IgG2a ratios
The skewing of IgG1/IgG2a ratios as depicted in Figs. 1
and 2 was further confirmed in the experiment described
above. The total IgG responses against CGG and TNP were
similar to the data presented in Fig. 1, although the total IgG
response against CGG after oral administration of L. murines
in stationary phase to mice (n = 8) was more pronounced
(data not shown). From the previous experiments (Figs. 1
and 2) it was apparent that the IgG1/IgG2a ratio is indepen-
dent of the level of the total IgG response. This raised the
question whether the IgG1/IgG2a ratio is also independent
of the level of the IgG1 and IgG2a response per animal, i.e.
whether the ratio is constant. Therefore, in Fig. 3, the IgG1
response of individual animals is depicted against the IgG2a
response of the same animal, with each circle representing an
individual animal. As comparable observations were made
Fig. 4. IgG subclass skewing by stationary phase L. murines decreases but
persists over time. The ratio of IgG1 and IgG2a antibodies specific for
CGG was calculated for sera obtained 7, 14 and 21 days after the second
immunization. (A) IgG1/IgG2a ratio of response against CGG in mice
fed L. murines in log phase (±S.E.M.). (B) IgG1/IgG2a ratio of response
against CGG in mice fed L. murines in stationary phase (±S.E.M.). The
IgG1/IgG2a ratio decreased significantly (P < 0.05) over time when
L. murines in stationary phase was fed (R = −1.04), in contrast to a
similar IgG1/IgG2a ratio over time when L. murines in log phase was
fed (R = −0.07).
for time points 7, 14 and 21 days, only data are shown from
groups which received L. murines in log or stationary phases
21 days after the second immunization. Two conclusions can
be drawn from this figure: first, there is a strong correlation
between the IgG1 and IgG2a response of each individual
animal within an experimental group (variance = 0.67 for
the group fed log phase cultures and variance = 0.85 for the
group fed stationary phase cultures), despite considerable
differences in IgG1 and IgG2a responses between the ani-
mals. This strong correlation indicates that the IgG1/IgG2a
ratio of individual animals within an experimental group is
highly comparable. This was demonstrated not only for the
groups fed L. murines but also for the control groups fed
buffer only. Second, the different slopes of the correlation
lines of the groups fed log phase (R = 0.43) or stationary
phase (R = 2.43) L. murines indicate that the IgG1/IgG2a
ratios between those groups are different (see Figs. 2 and 4)
confirming that the growth phase of orally administered lac-
tobacilli differentially affects the antibody response. This is
functionally relevant with respect to the differential effector
functions of IgG1 versus IgG2a Fc-moieties (e.g. comple-
ment fixation).
3.5. IgG subclass skewing by stationary phase L. murines
decreases but persists over time
In order to investigate whether the antigen specific
IgG1/IgG2a ratios persist over time, the IgG1/IgG2a ratio
was calculated for sera obtained at 7, 14 and 21 days after
the booster immunization. When the ratios were compared
over time, the group fed L. murines in log phase (Fig. 4(A))
showed a significantly lower IgG1/IgG2a ratio than the
stationary phase fed group (Fig. 4(B); intercept difference
with P < 0.05). This is consistent with the data presented
in Fig. 2. Furthermore, the IgG1/IgG2a ratio decreased
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significantly with time when L. murines in stationary phase
were administered (R = −1.04), in contrast to a comparable
IgG1/IgG2a ratio over time when L. murines in log phase
was given (R = −0.07; slope difference with P < 0.05).
This change in IgG1/IgG2a ratio over time was not seen
in the control groups (R = 0.06 for the buffer fed group
and R = 0.02 for the group immunized with TNP–CGG in
adjuvant).
3.6. Perspectives
This study shows that orally administered individual
Lactobacillus strains are able to differentially affect IgG1
versus IgG2a antibody responses against a thymus depen-
dent antigen, dependent on the Lactobacillus growth phase.
Stationary phase cultures showed increased production of
IgG1, which was evident even while the Th1-biased SJL/J
mouse strain was used. The most likely explanation for
these findings is the occurrence of growth phase-dependent
differences in bacterial cell wall composition, for which
there is ample prior evidence, including proinflammatory
compounds such as peptidoglycan and teichoic acids, induc-
ing distinct cytokine patterns [20–24]. Also factors involved
in bacterial adhesion and colonization might play a role
[25]. Another not mutually exclusive explanation is that
log phase versus stationary lactobacilli differentially affect
dendritic cell populations (DC1 versus DC2), which govern
directional activation and polarization of T-cell subsets dur-
ing antigen presentation [26]. This possibility is supported
by the recent findings that Lactobacillus strains can differ-
entially affect cytokine and MHC-II expression in DC [27].
Growth phase dependent skewing of T helper cell path-
ways has important consequences for industrial application
of Lactobacillus strains, as skewing may affect desired
probiotic activities of food products. With respect to im-
munotherapeutic applications, including genetically engi-
neered lactobacilli, our data caution that oral administration
may inadvertently promote autoimmune or allergic reac-
tions. However, this property of some Lactobacillus strains
may also offer promising opportunities for immune mod-
ulation. Oral vaccination strategies [28,29] may exploit
skewing properties to enhance T helper cell pathways de-
pendent on the desired protective response, for example,
induction of cell mediated immunity versus antibody pro-
duction, or preferential induction of specific functional IgG
subclasses (e.g. differential complement fixation by IgG1
versus IgG2a). Oral Lactobacillus administration strategies
for peripheral T-cell tolerance induction as a treatment of
autoimmune disease [1,14] may benefit from skewing to-
wards Th2 responses, whereas reduction of Th2 activity is
required in treatment of allergy. In a study submitted for
publication, we extend these findings by showing that Lacto-
bacillus recombinants expressing myelin epitopes can pos-
itively modulate T-cell reactivity in a disease model, using
Th1-mediated experimental autoimmune encephalomyelitis
(EAE).
The current findings strongly emphasize the need for ra-
tional Lactobacillus strain selection and detailed evaluation
prior to application in food or health care products, and im-
ply that the bacterial growth phase is a crucial parameter
allowing additional manipulation of immune responses by
oral administration of lactobacilli.
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